Lipid management for primary and secondary stroke prevention consensus paper of the International Lipid Expert Panel (ILEP) [0.03%]
国际脂质专家组(ILEP)共识文件：一线和二线的卒中预防以进行血脂管理
Maciej Banach,Peter P Toth,Hyo-Jeong Ahn et al.
Maciej Banach et al.
Ischemic stroke is a significant global health challenge, accounting for approximately 66 % of all strokes worldwide. Recent data indicates that stroke was the third leading cause of death (10.7 % of all deaths), following ischemic heart di...
Redefining nuclear cardiology: Bridging innovation, evidence, and practice [0.03%]
重新定义核素心肌显像：创新、证据和实践之间的桥梁
Panithaya Chareonthaitawee,Mouaz H Al-Mallah,Leandro Slipczuk
Panithaya Chareonthaitawee
Left ventricular wall thickness and derived parameters in cardiac amyloidosis [0.03%]
心脏淀粉样变性患者的左心室壁厚度及衍生参数变化规律
Michel Chedid El Helou,J Emanuel Finet,Joseph Kassab et al.
Michel Chedid El Helou et al.
Background: Left ventricular wall thickness (LVWT) is a key echocardiographic parameter in the diagnosis of cardiac amyloidosis (CA), yet its measurement is prone to variability, and traditional thresholds may miss early ...
Outcomes of TAVR in severe aortic stenosis: Very low gradient is not necessarily good news [0.03%]
主动脉瓣狭窄经导管主动脉瓣植入术的低收缩期峰值速度和低压力阶差
Philippe Pibarot
Philippe Pibarot
Silence is not always Golden: Should we perform catheter ablation in asymptomatic atrial fibrillation? Clinical debate and emerging evidence [0.03%]
沉默并不总是一种美德——对无症状房颤电生理消融的思考：临床观点与证据综述
Marco Schiavone,Luigi Di Biase
Marco Schiavone
Atrial fibrillation (AF) is a growing global health burden and a leading cause of morbidity and mortality. A significant proportion of AF episodes are asymptomatic or subclinical, leading to underdiagnosis and delayed treatment. Despite tra...
Chaitanya Rojulpote,Sarah A M Cuddy,Marie Foley Kijewski et al.
Chaitanya Rojulpote et al.
Cardiac amyloidosis is increasingly recognized as an underdiagnosed cause of heart failure. This review article provides an overview of the role of multimodality cardiovascular imaging in raising the suspicion of cardiac amyloidosis, confir...
Comparative effectiveness of sodium-glucose cotransporter 2 inhibitor and colchicine [0.03%]
钠葡萄糖协同转运蛋白2抑制剂与秋水仙碱的效果比较研究
Kuan-Fu Liao,Shih-Wei Lai
Kuan-Fu Liao
Timing of transcatheter aortic valve replacement after balloon aortic valvuloplasty: Insights from a multicenter real-world cohort [0.03%]
经导管主动脉瓣置换术在球囊主动脉瓣成形术后的时间选择：来自多中心真实世界队列的启示
Osamah Badwan,Akiva Rosenzveig,Fawzi Zhgyer et al.
Osamah Badwan et al.
Leandro Slipczuk
Leandro Slipczuk
The colchicine-sodium-glucose cotransporter two inhibitors conundrum: Promise, pitfalls, and next steps [0.03%]
秋水仙素-钠葡萄糖共转运蛋白2抑制剂困境：希望、陷阱和下一步措施
Ali Bin Abdul Jabbar,Asma Ahmed,Salim S Virani
Ali Bin Abdul Jabbar